

## Applied DNA Sciences Achieves ISO 9001:2008 Quality Management System Certification

Demonstrate Their Quality Commitment to Continuous Improvement in Secure DNA Design and Manufacturing

**STONY BROOK, NY. September 15, 2015.** Applied DNA Sciences, Inc. (NASDAQ: APDN) (Twitter: @APDN), a provider of DNA-based anti-counterfeiting technology, product genotyping services and product authentication solutions, announced today it had received ISO 9001:2008 certification for the Design and Manufacturing of DNA embedded concentrates, solutions and suspensions (and related authentication services) to be used in various security applications.

Certification is especially important to our strategic business plan as we expand our efforts to compete in the global marketplace. Achieving ISO 9001:2008 certification clearly demonstrates APDN's company-wide commitment to providing quality products and services to all current and future customers.

Public health and safety agency NSF International ([www.nsf.com](http://www.nsf.com)), one of the most respected independent certification organizations in existence today, completed their assessment of Applied DNA Sciences and deemed APDN to meet or exceed the international quality standard ISO 9001:2008. Not only is this a milestone in APDN's history, but it globally recognizes them as being the first (plant derived) DNA manufacturing security company to ever have achieved such a distinction.

ISO 9001:2008 certifications require a third-party accredited, auditing organization to thoroughly review the company's internal quality management system to ensure they are capable of delivering services that meets or exceeds their customers' needs and expectations. "NSF has confirmed what we knew all along- that Applied DNA Sciences is committed to Quality, Integrity and the Success of our customers. I applaud the tremendous efforts of our dedicated employees on achieving this goal," commented Dr. James Hayward, President and CEO of APDN.

### About Applied DNA Sciences



We make life real and safe by providing botanical-DNA based security and authentication solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. SigNature<sup>®</sup> DNA describes the platform ingredient that is at the heart of all of our security and authentication solutions. SigNature DNA is at the core of a family of uncopiable products such as DNA<sup>net</sup><sup>®</sup>, our anti-theft product, SigNature<sup>®</sup> T and fiberTyping<sup>®</sup>, targeted toward textiles, and digitalDNA<sup>®</sup>, providing powerful track and trace. All provide a forensic chain of evidence and can be used to prosecute perpetrators.

Applied DNA Sciences common stock is listed on NASDAQ under the symbol APDN, and its warrants are listed under the symbol APDNW.

### **Forward Looking Statements**

The statements made by APDN in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe APDN’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 15, 2014, as amended on March 6, 2015, and our subsequent quarterly reports on Form 10-Q filed on February 9, 2015, May 11, 2015 and August 10, 2015, which are available at [www.sec.gov](http://www.sec.gov). APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.



**investor contact:** Debbie Bailey, 631-240-8817, [debbie.bailey@adnas.com](mailto:debbie.bailey@adnas.com)

**media contact:** Susan Forman, Dian Griesel Int'l., 212-825-3210, [sforman@dgicomm.com](mailto:sforman@dgicomm.com)

**web:** [www.adnas.com](http://www.adnas.com)

**twitter:** @APDN